Autism is known as a “spectrum” disorder because there is wide variation in symptoms, skills and levels of impact people experience.
The estimated UK prevalence of ASD is 1% and because of its early onset, lifelong persistence, and high levels of associated impairment, it is recognised as a major public health concern.
There are many claims of a 'cure' for autism, all of which are without foundation. However, there are interventions that can help some of the core features of autism, some of the symptoms, behaviours and problems commonly associated with autism, and support families and carers.2 Many individuals with ASD have psychiatric symptoms that do not form part of the diagnostic criteria for the disorder; it is recognised that about 70% of individuals with ASD impairment may have one comorbid mental disorder and 40% may have two or more comorbid mental disorders. Medical conditions commonly associated with ASD include epilepsy, sleep problems and constipation.1 Identification of comorbidities may provide targets for specific interventions to reduce overall impairment and improve quality of life.
Flynn Pharma is committed to the delivery of high quality medical educational events that support the continued development of healthcare professionals - it's our way of helping you to help your patients. Don't miss out. Flynn continues to host a series of educational events and webinars around ASD and other neurodevelopmental disorders that are free for healthcare professionals to attend. Sign up to receive our latest updates.
London Neurodevelopmental Disorders Study Day 2023
Midlands Neurodevelopmental Disorders Study Day
Become an NDD Community Member
Join our community as a Member and keep up to date on the latest developments.
Insomnia in paediatric ASD
Slenyto® Treatment Goals and Therapy Optimisation – A Guide for Healthcare Professionals
Insomnia in children with ASD is perceived to be one of the most challenging health effects of autism and a successful intervention needs to define realistic and agreed outcomes that can be systematically monitored. This simple guide ...
Slenyto® Therapeutic Bulletin
A succinct summary of the evidence-base for Slenyto® (paediatric prolonged-release melatonin) for the treatment of insomnia in children and adolescents with Autistic Spectrum Disorder ...
1. Diagnostic and Statistical Manual of Mental Disorders, 5th edition: DSM-5. American Psychiatric Association, 201
2. NICE Clinical guideline CG170 Autism spectrum disorder in under 19s: support and management. Published August 2013